From Insight to Impact: Equilab International Elevates Asia’s Pharma Landscape with Bioanalytical Expertise

As a leading Bioequivalence Centre in Indonesia and Southeast Asia, Equilab International was honored to be one of the speakers at the Asia Pacific Pharma Executive Forum 2025, held in Nusa Dua, Bali, on October 15–16, 2025.

Equilab’s Group Analytical Manager, Mr. Yantirta Indra Kurniawan, S.Si, M.Biomed, shared a presentation on “The Critical Role of the Bioanalytical Aspect in Drug Development” to participants from South East Asian countries, India, Japan, Korea, Australia, and beyond. The session highlighted the importance of reliable bioanalytical methods in generating accurate pharmacokinetic data that support drug development. Bioanalytical methods play a crucial role in Bioequivalence and Pharmacokinetic studies, which are key components of drug development especially for Innovative Products (e.g., Semaglutide). Their primary purpose is to accurately and reliably measure drug levels, metabolites, and biomarkers in biological samples, such as blood, plasma, and urine. Reliable data is essential for the clinical decision-making process in drug development and ensures patient safety and efficacy.

With strong bioanalytical expertise, Equilab helps Asian pharma companies to accelerate their drug development, especially for innovative drugs with various dosage forms. At Equilab, we continuously strengthen our bioanalytical capabilities with more than 300 validated methods, modern facilities, and experienced team. Equilab commits to ensure high quality and faster timeline of Bioequivalence and Pharmacokinetic studies.  Equilab truly appreciate the opportunity to share knowledge and connect with pharma executives from across the Asia Pacific region.